Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DanaherXSWX:DHR +0.97%79 FCF Margin % is 20.19% as of Jun. 2026, which is 7% below its 10-year median of 21.80. GuruFocus rates XSWX:DHR with a GF Score™ of 79/100 and a GF Value™ of CHF193.13. The stock has 4 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Danaher ranks better than 91.63% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Danaher's Free Cash Flow for the
three
months ended in Jun. 2026 was CHF1,011 Mil. Danaher's Revenue for the
three
months ended in Jun. 2026 was CHF5,008 Mil. Therefore, Danaher's FCF Margin % for the quarter that ended in Jun. 2026 was 20.19%.
The historical rank and industry rank for Danaher's FCF Margin % or its related term are showing as below:
XSWX:DHR'
s FCF Margin % Range Over the Past 10 Years
Min: 17.37 Med: 21.8 Max: 28.7
Current: 21.78
During the past 13 years, the highest FCF Margin % of Danaher was 28.70%. The lowest was 17.37%. And the median was 21.80%.
XSWX:DHR's FCF Margin % is ranked better than 91.63% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.96
vs XSWX:DHR: 21.78
The historical data trend for Danaher's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Danaher's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Danaher FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Danaher's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Danaher's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Danaher (XSWX:DHR) has a FCF Margin % of 20.19% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Danaher and its competitors. This is near median its historical median of 21.80. Over the past decade, Danaher's FCF Margin % has ranged from 17.37 to 28.70. According to the industry distribution chart, Danaher ranks #17 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 8.4%.
Is Danaher's FCF Margin % too high?
Danaher's current FCF Margin % of 20.19% is near median its 10-year median of 21.80. Over the past 10 years, this metric has ranged from a low of 17.37 to a high of 28.70. Based on the distribution chart, Danaher ranks #17 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Danaher has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Danaher's FCF Margin % compare to TMO and IDXX?
According to the Medical Diagnostics & Research industry distribution chart, Danaher ranks #17 out of 203 companies for FCF Margin %. This places Danaher in the top 8% of its industry — outperforming the majority of peers. Historically, Danaher's own FCF Margin % has ranged from 17.37 to 28.70 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Danaher and its competitors. Danaher's current FCF Margin % is 20.19%, which is near median its own 10-year median of 21.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Danaher stock overvalued right now?
Danaher (XSWX:DHR) has a current FCF Margin % of 20.19%. The stock's GF Value™ is CHF193.13, compared to a current price of CHF158.80 — trading 17.8% below its estimated fair value. The current FCF Margin % is 20.19%, which is near median its 10-year median of 21.80. Danaher's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Danaher (XSWX:DHR), the current FCF Margin % is 20.19% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Danaher (XSWX:DHR) Overvalued in 2026?
Based on GuruFocus' analysis, Danaher stock appears to be undervalued.
The current stock price of CHF158.80 is trading 17.8% below its estimated GF Value™ of CHF193.13.
Key valuation signals for XSWX:DHR:
FCF Margin %: 20.19% (near median its 10-year median of 21.80)
GF Value™: CHF193.13 vs. price of CHF158.80 (17.8% below fair value)
No single metric tells the full story. See the XSWX:DHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
79GF Score
Get the complete analysis for XSWX:DHR
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:DHR has been successfully added to your 
